Advances in Therapy
IF
3.87
Papers
2447
Papers 2942
1 page of 295 pages (2,942 results)
Newest
#1Yeon Kyeong ShinH-Index: 1
#2Won Yong HanH-Index: 1
view all 8 authors...
CT-P17 (Celltrion, Inc., Incheon, Republic of Korea) is a biosimilar of reference adalimumab (Humira®; AbbVie Inc., North Chicago, IL, USA), which has recently received regulatory approval from the European Medicines Agency. This analysis was designed to evaluate the stability profile of CT-P17 compared with reference adalimumab and the currently licensed adalimumab biosimilars ABP 501 (Amjevita®/Amgevita®; Amgen Inc., Thousand Oaks, CA, USA) and SB5 (Imraldi®; Biogen Inc., Cambridge, MA, USA) w...
Source
#1Rubeen Israni (AstraZeneca)
#2Keith A. Betts (AG: Analysis Group)H-Index: 16
Last. Eric Q. Wu (AG: Analysis Group)H-Index: 58
view all 10 authors...
The progression of mild hyperkalemia and the predictors of progression have not been well characterized. In this study we aimed to characterize the progression of hyperkalemia and identify the risk factors for hyperkalemia progression. Adults with mild hyperkalemia (at least one serum potassium measure > 5.0 and ≤ 5.5 mEq/L) were identified using electronic medical records from the Research Action for Health Network (2012–2018). Progression to moderate-to-severe and progression to severe hyperka...
Source
#1Robert L. Ohsfeldt (A&M: Texas A&M University)H-Index: 34
#2Casey Choong (Eli Lilly and Company)H-Index: 2
Last. Russel Burge (UC: University of Cincinnati)H-Index: 16
view all 6 authors...
Introduction null Reliable cost and resource use data for COVID-19 hospitalizations are crucial to better inform local healthcare resource decisions; however, available data are limited and vary significantly. null Methods null COVID-19 hospital admissions data from the Premier Healthcare Database were evaluated to estimate hospital costs, length of stay (LOS), and discharge status. Adult COVID-19 patients (ICD-10-CM: U07.1) hospitalized in the US from April 1 to December 31, 2020, were identifi...
Source
#1Konstantin Drexler (University Hospital Regensburg)H-Index: 6
#2Hans Drexler (FAU: University of Erlangen-Nuremberg)H-Index: 48
Last. Christian Apfelbacher (Otto-von-Guericke University Magdeburg)H-Index: 40
view all 6 authors...
Malignant melanoma is an aggressive skin tumor with a good prognosis when treated in an early tumor stage, but has a poor prognosis with distant metastases. The incidence of malignant melanoma has increased continuously over the last decades, with little change in mortality. One explanation for this is that melanomas are increasingly detected in early stages, especially after the establishment of statutory skin cancer screening in 2008, which allows a free skin examination every 2 years for peop...
Source
#1Tomohiro OgamiH-Index: 2
#2Hiroki AsanoH-Index: 1
Last. Tetsuro Oshika (University of Tsukuba)H-Index: 74
view all 5 authors...
This study evaluated the efficacy and safety of diquafosol ophthalmic solution (DQS) in soft contact lens (SCL)-related dry eye using artificial tear as a control. This study enrolled 26 patients with SCL-related dry eye. DQS and artificial tears (AT) were instilled into the right and left eyes, respectively, with their SCLs on. Dry eye examinations (including tear film breakup time, tear volume, and staining score) were performed and visual function (including contrast sensitivity) was also eva...
Source
#1Alexander T. Cohen (Guy's and St Thomas' NHS Foundation Trust)H-Index: 59
#2Janvi SahH-Index: 1
Last. Xuemei Luo (Pfizer)H-Index: 22
view all 10 authors...
Impact of demographics and socioeconomic status (SES) on anticoagulant treatment outcomes among patients with venous thromboembolism (VTE) is not well understood. This study evaluated risks of recurrent VTE, major bleeding (MB), and clinically relevant non-major bleeding (CRNMB) among older patients with VTE initiating apixaban or warfarin stratified by demographics and SES. Adult patients (≥ 65 years) who initiated apixaban or warfarin after a VTE event were selected from the US CMS Medicare da...
Source
#1Millie Das (VA Palo Alto Healthcare System)H-Index: 10
#2Sukhmani K. Padda (Cedars-Sinai Medical Center)
Last. Taofeek K. Owonikoko (Emory University)H-Index: 59
view all 4 authors...
Second-line treatment options for patients with relapsed, extensive-stage small cell lung cancer (ES-SCLC) are limited, and even with currently available treatments, prognosis remains poor. Until recently, topotecan (a topoisomerase I inhibitor) was the only drug approved by the United States (US) Food and Drug Administration (FDA) for the management of ES-SCLC following progression after first-line treatment with etoposide plus a platinum derivative (EP; carboplatin preferred). With the most re...
Source
#1Alberto Esquenazi (Albert Einstein Medical Center)H-Index: 31
#2Ziyad Ayyoub (Western University of Health Sciences)H-Index: 3
Last. Atul T. PatelH-Index: 7
view all 6 authors...
INTRODUCTION The safety and efficacy of both abobotulinumtoxinA and onabotulinumtoxinA for upper limb spasticity are well established, but head-to-head comparisons are lacking. METHODS DIRECTION is an international, randomized, double-blind, crossover study comparing the safety and efficacy of abobotulinumtoxinA with onabotulinumtoxinA in the management of upper limb spasticity at doses at or near maximum recommended in product labelling. Participants (18-75 years) will be randomized (1:1) to ei...
Source
#1Thibaud PrawitzH-Index: 2
#2Rakesh Popat (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 18
Last. Jenny Willson (GSK: GlaxoSmithKline)H-Index: 1
view all 11 authors...
Single-agent belantamab mafodotin (belamaf; BLENREP) demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma and ≥ 3 prior lines of therapy, including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody (DREAMM-2; NCT03525678). At the time of this study, STORM Part 2, NCT02336815 (selinexor plus low-dose dexamethasone; sel + dex) was systematically identified as the only feasible comparator to the DREAMM-2 cohort. Matching-adjusted indire...
Source
#1Chao Hu (Sichuan University)H-Index: 1
#2Xiaofeng Ou (Sichuan University)
Last. Jia Miao (Sichuan University)H-Index: 2
view all 8 authors...
The effects of continuous infusions of ciprofol on its pharmacodynamic and pharmacokinetic properties and safety profiles in healthy Chinese subjects were evaluated. In this open-label, randomized, two-way cross-over study, subjects received initial doses of continuous ciprofol/propofol as an infusion for 30 min in part 1 (n = 8) and a bolus dose in part 2 (n = 8) followed by maintenance infusions for a total of 4 h in part 1 and 12 h in part 2. Each subject participated in both parts with a was...
Source
12345678910
Top fields of study
Internal medicine
Surgery
Intensive care medicine
Adverse effect
Rheumatology
Anesthesia
Diabetes mellitus
Medicine